Genkyotex SA (GKTX.PA)

3.205 €

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol GKTX.PA
Price 3.205 €
Beta 0.948
Volume Avg. 0.01M
Market Cap 45.108M
Shares () -
52 Week Range 2.525-4.84
1y Target Est -
DCF Unlevered GKTX.PA DCF ->
DCF Levered GKTX.PA LDCF ->
ROE -122.34% Strong Sell
ROA -136.02% Strong Sell
Operating Margin -
Debt / Equity 209.22% Strong Buy
P/E -
P/B 13.36 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Ilias Papatheodorou
Healthcare
Biotechnology
Paris

Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Labège, France.